272 results on '"Seghatchian, Jerard"'
Search Results
2. Editorial commentary
3. Editorial commentary – A snapshot on the role of newer technologies identifying variability in donor red cell storage stability and its implications on recipients’ clinical outcome
4. An invite for evidence-based insights and expert viewpoints on blood donor recruitment and retention
5. Spotlight on the impact of transfusion support, the detrimental influence of blood donation microbiomes on hematological immune-related toxicities, and the sustained efficacy and survival outcomes of immune checkpoint inhibitors’ treated cancer patients
6. T-cell lymphocytopenia: an omnipresent predictor of morbidity and mortality in consequence of SARS-CoV disease and influenza A infections
7. Spotlight on SARS CoV-2 infection inducing autoimmunity, through the formation of autoantibody to self hemostatic components or to host cells, often leading to severe thrombotic or bleeding events
8. Hematological toxicities of immune checkpoint inhibitors and the impact of blood transfusion and its microbiome on therapeutic efficacy and recipient’s safety and survival outcome:A systematic narrative appraisal of where we are now!
9. Spotlight on the impacts of transfusion on patients with Autoimmune Rheumatic Diseases
10. Spotlights on the latest opinions on identification, prevention, and management of newer CoV-2 variants: A roundup appraisal on innovative ideas and designer vaccines for Omicron
11. Blood transfusion in autoimmune rheumatic diseases
12. Autoimmune complications of COVID-19 and potential consequences for long-lasting disease syndromes
13. Do highly transmissible omicron subtypes BA.4/BA.5 have any impact on the HLA class I /II antibodies of apheresis donors, and could mucosal omicron-specific vaccines prevent transmissibility and provide more durable protection?
14. Cryopreservation of apheresis platelets treated with riboflavin and UV light
15. SARS-CoV-2 and cancer: the intriguing and informative cross-talk
16. Editorial: Time to explore the missing links: the cross-talk between COVID infection and cancer cells; lingering questions on the longitudinal efficacy of the front line immunotherapies against unpredictable “Omicron ghosts” and insights from CAR-T cell therapy pointing toward better clinical outcomes
17. Platelet and extracellular vesicles in COVID-19 infection and its vaccines
18. What’s Is Happening Section [Trasci.61.3]
19. An all-round appraisal of the latest viewpoints on “Acute Thrombotic Coagulability” and an update on the “inflammation-conditioned” profiles of platelets in sepsis patients
20. An appraisal of the latest achievements on platelet lysate designed for clinical opportunities in regenerative medicine and cellular therapy
21. Cryopreservation of Apheresis Platelets Treated with Riboflavin and UV Light
22. Spotlights on “Process Capability Index Trends”: A new development in the manufacturing of blood components and related industries
23. Spotlight on the latest trends on CoV-2 Alpha and Delta variants in the UK; Targeting blood donor population for assessing the effect of the mRNA vaccines on the seroprevalence of CoV-2 Delta variant antibodies and reflections on the management of alloimmunisation in transfused patients with constitutional anaemias in Norway
24. Back to basics on assessment of extracellular vesicle activity states, using modern captured based assays, combined with innovative IFC and proteomics, that might become tomorrow’s realities
25. Exploratory spotlights on the proteome of extracellular vesicles in red blood cell units prepared by the same donors revealed that leukoreduction may matter for the quality and safety of transfusion therapy: Back to basics for research topics that might begin tomorrow’s realities
26. Facts and challenges on global deployment of vaccines for the immunotherapy of the evolving SARS Cov-2 variants: What a new year, with a fast spreading South African and the most fearful Brazilian variants, as the unwanted gifts, imposing enormous crises to surmount
27. New generation of vaccines and convalescent plasma therapy for management of CoV-2: Perspectives from the UK and potential deployment in the current global pandemic
28. An introductory commentary on the use of artificial intelligence, machine learning and TQM, as novel computational tools in big data patterns or procedural analysis, in transfusion medicine
29. Assessment of extracellular vesicles using IFC for application in transfusion medicine
30. An Overview of Current Position on Cell Therapy in Transfusion Science and Medicine: From Fictional Promises to Factual and Perspectives from Red Cell Substitution to Stem Cell Therapy
31. Updates on Stem Cell Therapy in Transfusion Medicine, New Approaches to RBC Substitution Therapy, the Use of IFC for the Assessment of Extracellular- Derived Vesicles/Exosomes
32. Update on newer approaches to prevent or treat COVID-19 infection: What we all need the most right now!!
33. Trends and targets of various types of stem cell derived transfusable RBC substitution therapy: Obstacles that need to be converted to opportunity
34. An update on COVID-19 infection control measures, plasma-based therapeutics, corticosteroid pharmacotherapy and vaccine research
35. Spotlight on the current perspectives on applications of human blood cell culture and organoids: Introductory remarks
36. In vitro platelet production for transfusion purposes: Where are we now?
37. In vitro mass production of reproducible human cells destined for substitution therapy: Challenges for development of functional materials for what we need most in transfusion!
38. Cell culture – Fact and fiction
39. The secrets of human stem cell-derived transfusable RBC for targeted large-scale production and clinical applications: A fresh look into what we need most and lessons to be learned
40. Shedding light on the quality profiles of stem cells, whole blood and the supply of cryopreserved blood-derived bioproducts
41. Opportunities for standardization of cold stored, low-titre group O WB products
42. Emergency Supply Policy of Cryopreserved RBC and PLT: The Czech Republic Concept
43. Covid-19, induced activation of hemostasis, and immune reactions: Can an auto-immune reaction contribute to the delayed severe complications observed in some patients?
44. When I need you most: frozen red blood cells for transfusion
45. Insights on Policies for Stem Cell and Frozen Blood Bioproducts
46. Optimizing the supply of whole blood-derived bioproducts through the combined implementation of cryopreservation and pathogen reduction technologies and practices: An overview
47. Poor economics - Transforming challenges in transfusion medicine and science into opportunities
48. Platelet-derived bio-products: Classification update, applications, concerns and new perspectives
49. The state of plasma fractionation in technologically disadvantaged countries and current perspectives on the classification and applications of platelet-derived bio-products used in regenerative medicine
50. Vitamin B12 deficiency and metabolism-mediated thrombotic microangiopathy (MM-TMA)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.